3E Bioventures Develops RNA & Protein Drug Separately
09 Jun 2026
US$ 20.00
3E Bioventures and Shanghai State-owned Capital Investment Co Ltd have co-led the angel+ financing round of ......
Related Publications
Subscribers’ Weekly for the week ending 12 June 2026...
Peak XV Partners, through its seed investment platform, Surge, has led the US$5 m funding round in Hoola Health. The...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.